Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v4-EN | Version v3-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2025-01-07 | 2024-10-02 |
| Drug Identification Number | 01981242 | 01981242 |
| Brand name | DESFERAL 500MG | DESFERAL 500MG |
| Common or Proper name | DESFERAL VIALS 500MG 1 X 10 | DESFERAL VIALS 500MG 1 X 10 |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC | NOVARTIS PHARMACEUTICALS CANADA INC |
| Ingredients | DEFEROXAMINE MESYLATE | DEFEROXAMINE MESYLATE |
| Strength(s) | 500MG | 500MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAPERITONEAL INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAPERITONEAL INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAPERITONEAL INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAPERITONEAL INTRAMUSCULAR |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 1 x 10 | 1 x 10 |
| ATC code | V03AC | V03AC |
| ATC description | ALL OTHER THERAPEUTIC PRODUCTS | ALL OTHER THERAPEUTIC PRODUCTS |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2024-10-01 | 2024-10-01 |
| Actual start date | ||
| Estimated end date | ||
| Actual end date | 2025-01-06 | 2025-01-06 |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Product on allocation to minimize patient's impact | Product on allocation to minimize patient's impact |
| Health Canada comments |